$1.57+0.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Company outlook: revenue of $13.5M to $14.5M for Fiscal year 2026 — down 15.6% on a year earlier ($16.6M)
Just reported
From Seer, Inc.'s results release of November 10, 2026; its quarterly report has since been filed.
Actual
$4M
-3.4% y/y
+28% q/q
Guided
—
No guide given
Actual
-$14.7M
Guided
—
No guide given
Full year 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $4M | $4.1M | -3.40% |
| Profit | -$13.7M | -$18.2M | +24.66% |
| Free Cash Flow | -$10M | -$7.8M | -26.98% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Seer, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Seer, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.